NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 104,467 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at $2,099,850.60. This represents a 60.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, March 9th, Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61.
• On Friday, March 6th, Johannes Jacob Piete Kastelein sold 94,124 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.32, for a total value of $2,853,839.68.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.31, for a total transaction of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $30.77 on Tuesday. The company’s fifty day moving average price is $33.48 and its 200-day moving average price is $33.32. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00. The company has a market capitalization of $3.54 billion, a PE ratio of -17.79 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Mather Group LLC. purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at approximately $30,000. Finally, Navalign LLC bought a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at approximately $46,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Leerink Partners restated an “outperform” rating and set a $55.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Stifel Nicolaus lifted their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Guggenheim increased their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.10.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.